RESPIRATORY AND NUTRITIONAL OUTCOMES DURING SMN-DIRECTED THERAPY IN PATIENTS WITH 5Q-SPINAL MUSCULAR ATROPHY

Authors

  • Mushtari Mirkhamitovna Kasimova Author
  • Khanifa Mukhsimovna Khalimova Author
  • Nilufar Safaevna Rashidova Author

Keywords:

patients, respiratory, motor, nutritional, group, treatment, earlier, outcomes, therapy, included

Abstract

Spinal muscular atrophy (SMA) is a progressive hereditary neuromuscular disorder caused predominantly by biallelic pathogenic variants of the SMN1 gene. Deficiency of functional survival motor neuron protein results in progressive degeneration of α-motor neurons, producing symmetrical muscle weakness, muscular atrophy and progressive loss of motor abilities. Although impairment of motor function represents the most evident clinical manifestation of SMA, respiratory, bulbar and nutritional complications are also major determinants of disease burden and long-term prognosis.

References

During 12 months of SMN-directed therapy, patients who began

treatment earlier demonstrated a tendency toward better respiratory stability and more

favorable nutritional outcomes than patients with delayed treatment initiation. The

proportions of patients remaining free from permanent ventilation, severe respiratory

hospitalization and nutritional deterioration were numerically higher in the earliertreatment group. However, unlike motor outcomes, most differences in respiratory and

nutritional endpoints did not reach statistical significance. These findings support a

comprehensive model of SMA management in which early pathogenetic treatment is

combined with continuous multidisciplinary respiratory, nutritional, neurological and

rehabilitative care.

Published

2026-09-06